US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress
Executive Summary
Past year was the high-water mark for product approvals and launches, but complete response letters remain a frequent occurrence. FDA’s ability to deliver on its promise of further clarity on transition products, interchangeability and indication carve-outs/carve-ins may take a hit from the ongoing partial government shutdown. On the legal side, look for more patent settlements with staggered entry dates and new antitrust scrutiny.
You may also be interested in...
US Biosimilar Fee Collections Fall Short
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
The latest drug development news and highlights from our US FDA Performance Tracker.